Beta Bionics, Inc. Common Stock Asset Resilience Ratio
Beta Bionics, Inc. Common Stock asset resilience ratio. Beta Bionics, Inc. Common Stock (BBNX) has an Asset Resilience Ratio of 46.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beta Bionics, Inc. Common Stock (BBNX) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Beta Bionics, Inc. Common Stock (2022–2025)
Asset resilience ratio of Beta Bionics, Inc. Common Stock from 2022 to 2025. This chart shows how Beta Bionics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read total liabilities of Beta Bionics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Beta Bionics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Beta Bionics, Inc. Common Stock asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $136.17 Million | 46.57% |
| Total Liquid Assets | $136.17 Million | 46.57% |
Asset Resilience Insights
- Very High Liquidity: Beta Bionics, Inc. Common Stock maintains exceptional liquid asset reserves at 46.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Beta Bionics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Beta Bionics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Beta Bionics, Inc. Common Stock Asset Resilience Ratio by Year (2022–2025)
Beta Bionics, Inc. Common Stock asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Beta Bionics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.05% | $187.55 Million | $328.74 Million | +8.17pp |
| 2024-12-31 | 48.88% | $73.14 Million | $149.65 Million | -14.90pp |
| 2023-12-31 | 63.78% | $70.18 Million | $110.04 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $35.53 Million | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more